sellWeak cluster of 410b5-1 plan
Alfonso Quintas Cardama sold $10k of TCRR
Chief Medical Officer at TCR2 THERAPEUTICS INC.. 7,464 shares at an average of $1.35, traded Dec 5, 2022, filed Dec 7, 2022.
Warning score
10Value
$10k
7,464 shares
Holdings after
131,200
-5% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$10k at market
- 0Share of holdings soldSold 5.4% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000899243-22-037943, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 5, 2022 | SOpen-market sale Common Stock10b5-1 | -3,686 | $1.37 | $5,050 | 134,978 | Dec 7, 2022 |
| Dec 6, 2022 | SOpen-market sale Common Stock10b5-1 | -3,778 | $1.33 | $5,040 | 131,200 | Dec 7, 2022 |
Related signals
Other insiders at TCR2 THERAPEUTICS INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | TCRRbuy TCR2 THERAPEUTICS INC. | Kevin C Tang owner | $86k 50,000 shares | +1% | |
| 36Weak | TCR2 THERAPEUTICS INC. | Mpm Asset Management LLC owner | $132k 70,170 shares | -19% | |
| 39Weak | TCR2 THERAPEUTICS INC. | Ansbert Gadicke director, owner | $132k 70,170 shares | -19% | |
| 31Weak | TCRRbuy TCR2 THERAPEUTICS INC. | Kevin C Tang owner | $88k 44,948 shares | +1% | |
| 33Weak | TCRRbuy TCR2 THERAPEUTICS INC. | Kevin C Tang owner | $164k 83,988 shares | +2% | |
| 39Weak | TCRRbuy TCR2 THERAPEUTICS INC. | Kevin C Tang owner | $548k 289,577 shares | +7% | |
| 15Weak | TCR2 THERAPEUTICS INC. | Alfonso Quintas Cardama Chief Medical Officer | $15k 13,799 shares | -11% | |
| 15Weak | TCR2 THERAPEUTICS INC. | Angela Justice Chief People Officer | $9,448 8,620 shares | -15% | |
| 31Weak | TCR2 THERAPEUTICS INC. | Garry E Menzel President and CEO | $35k 31,938 shares | -19% | |
| 15Weak | TCR2 THERAPEUTICS INC. | Peter Olagunju Chief Technical Officer | $5,299 4,830 shares | -17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.